Ista Pharmaceuticals initiates Phase III clinical programme for Remura in dry eye disease.

Ista Pharmaceuticals Inc (Ista) has announced that it has initiated a Phase III clinical programme of Ista's proprietary formulation of Remura (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase III efficacy studies are being conducted under a special protocol assessment (SPA) agreed upon with the US Food and Drug Administration (FDA). Dry eye is a large and growing market, with 2010 worldwide prescription sales expected to be about $600 M. At this time, Ista plans to assess the safety and efficacy of Remura in alleviating the signs and symptoms of dry eye disease by conducting four randomized, double-masked, …